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A B S T R A C T
Introduction: Many clinicians are reluctant to use traditional mood-stabilizing agents, especially lithium,
in children and adolescents. This review examined the evidence for lithium’s safety and efficacy in this
population.
Methods: A systematic review was conducted on the use of lithium in children and adolescents with
bipolar disorder (BD). Relevant papers published through June 30th 2018 were identified searching the
electronic databases MEDLINE, Embase, PsycINFO and the Cochrane Library.
Results: 30 articles met inclusion criteria, including 12 randomized controlled trials (RCTs). Findings from
RCTs demonstrate efficacy for acute mania in up to 50% of patients, and evidence of long-term
maintenance efficacy. Lithium was generally safe, at least in the short term, with most common side
effects being gastrointestinal, polyuria, or headache. Only a minority of patients experienced
hypothyroidism. No cases of acute kidney injury or chronic kidney disease were reported.
Conclusions: Though the available literature is mostly short-term, there is evidence that lithium
monotherapy is reasonably safe and effective in children and adolescents, specifically for acute mania and
for prevention of mood episodes.
© 2018 Elsevier Masson SAS. All rights reserved.
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The diagnosis of bipolar disorder (BD) in children and
adolescents has been a controversial topic [1], with much concern
about risks of treating it [2], with concerns about the harms of
antipsychotic agents in particular [3]. An alternative to antipsy-
chotic agents would be mood-stabilizing drugs like lithium, yet* Corresponding author at: Department of Mental Health, Mental Health Service
of Fidenza, Via Berenini 153, Fidenza, Parma, Italy.
E-mail addresses: andrea.amerio@studenti.unipr.it (A. Amerio),
ossola.paolo@gmail.com (P. Ossola), scagnelli.fra@libero.it (F. Scagnelli),
anna.odone@mail.harvard.edu (A. Odone), marco.allinovi@gmail.com (M. Allinovi)
, a.cavalli@meyer.it (A. Cavalli), jessica.iacopelli@gmail.com (J. Iacopelli),
mtonna@ausl.pr.it (M. Tonna), carlo.marchesi@unipr.it (C. Marchesi),
nassir.ghaemi@tufts.edu (S.N. Ghaemi).
http://dx.doi.org/10.1016/j.eurpsy.2018.07.012
0924-9338/© 2018 Elsevier Masson SAS. All rights reserved.clinicians also are reluctant to use that agent, especially with
apprehension regarding cognitive side effects [4], as well as about
long-term medical risks, such as hypothyroidism and chronic renal
insufficiency [5]. Further, many clinicians seem to be sceptical
about the efficacy of lithium in children.
This paper seeks to shed light on these concerns, with the first
systematic review on the safety and efficacy of lithium in children
and adolescents with BD.
2. Materials and methods
As done before [6,7], this review was conducted according to
methods recommended by the Cochrane Collaboration and the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [8,9].
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Studies were identified searching the electronic databases
MEDLINE, Embase, PsycINFO and the Cochrane Library. We
combined the search strategy of free text terms and exploded
MESH headings for the topic of treatment with lithium in children
and adolescents combined as following: ((((((Lithium) OR Lithium
carbonate) OR Lithium carbonate[MeSH Terms])) AND (((Children)
OR Adolescent) OR Adolescent[MeSH Terms])) AND (((((((Bipolar
disorder) OR BD) OR Bipolar) OR Manic depressive disorder) OR
Manic depressive) OR Manic) OR Bipolar disorder[MeSH Terms]))
AND ((((treatment*) OR therap*) OR pharmacotherap*) OR
Therapeutics[MeSH Terms]). The strategy was first developed in
MEDLINE and then adapted for use in the other databases
(Appendix A in Supplementary material). Studies published in
English through June 30th 2018 were included. In addition, further
studies were retrieved from reference listing of relevant articles
and consultation with experts in the field.
2.2. Inclusion criteria
2.2.1. Study population and study design
We considered studies that included children and adolescents
with BD treated with lithium both in monotherapy and in
combination with others psychotropic drugs. BD was considered
if diagnostic criteria used were specified. Studies conducted on
youths with different disorders than BD (e.g. dysphoric mood
dysregulation disorder) were excluded (i.e. [10–12]:). Participants
of both sexes younger than 18 years of age were considered. Studies
conducted on subjects with physical comorbidities such as
epilepsy were excluded as non-representative of the study
population [13].
Among hospital-based studies, inpatients, day-hospital and
outpatient subjects were included, while emergency care records
were excluded as non-representative. All experimental and
observational study designs were included apart from case reports
and case series. Narrative and systematic reviews, letters to the
editor, and book chapters were excluded.
2.2.2. Outcomes
The primary outcome was lithium effectiveness in children and
adolescents with BD. Secondary outcomes were i) starting dose
and dosing strategy, ii) brain-to-serum lithium association, and iii)
safety and tolerability of lithium.
2.2.3. Study selection and data extraction
Identified studies were independently reviewed for eligibility
by two authors (AA, FS) in a two-step process: A first screening was
performed based on title and abstract, and then full texts were
retrieved for a second screening. At both stages disagreements by
reviewers were resolved by consensus. Data were extracted by two
authors (AA, FS) and supervised by a third author (SNG) using an
ad-hoc developed data extraction spreadsheet. The data extraction
spreadsheet was piloted on 10 randomly selected papers and
modified accordingly.
3. Results
Two hundred and twelve potential studies were identified
from the selected databases and after cross-checking references
of relevant articles. After removing duplicates, 152 articles were
retrieved. Studies were screened and selected on the basis of
pre-specified inclusion and exclusion criteria (Fig. 1). The
search identified 30 articles that were included in the systematic
review.3.1. Included studies
The characteristics of included studies are reported in Table 1.
Twelve (40%) of the 30 studies were randomized controlled trials
(RCTs) of which only one was longer than 6 months in duration.
Most studies (n = 19, 63%) were short-term (8 weeks or less), while
4 studies (13%) provided long-term data of 6 months or longer. The
smallest study included 6 subjects while the largest considered a
sample of 279 subjects. The majority of the studies were conducted
in North America (N = 28, 93%). In all the considered studies,
diagnosis were based on the Diagnostic and Statistical Manual
(DSM) criteria and were established using validated assessment
scales (Table 1).
3.2. Outcomes
Selected studies included children and adolescents with BD
treated with lithium. Both lithium monotherapy and lithium in
combination with adjunctive agents were included. Data about
starting dose and dosing strategy, brain-to-serum lithium associa-
tion, safety and tolerability were also reported (Table 2).
4. Bipolar illness
Thirty studies assessed the use of lithium in children and
adolescents with BD (Table 2). The majority of the selected studies
(N = 22/30, 73%) were conducted on BD patients treated with
lithium monotherapy. Eleven studies (37%) were specific for BD-I
patients.
4.1. Lithium monotherapy
4.1.1. Manic or mixed episodes
Three RCTs reported improvements in manic or mixed
symptoms and overall functioning in manic BD children and
adolescents with lithium treatment [14,20,21]. Over 50% of
patients met response and remission criteria in one out of three
of the cited studies [14]. These results were supported by three
prospective non-randomized cohort studies [18,22,23] and one
retrospective cohort study [24]. No significant difference in
exacerbation rates between subjects treated with lithium and
those switched to placebo was detected in only one RCT with a very
short stabilization period (two weeks) [25].
Considering bipolar subgroups, lithium effectiveness for manic
symptoms was greater in adolescent-onset compared to prepu-
bertal-onset patients in one study [23]. Manic adolescents with
comorbid attention deficit hyperactivity disorder (ADHD) showed
less robust and slower improvement with lithium compared to
non-comorbid patients, both in a randomized and in a non-
randomized trial [26,27]. In patients with substance abuse and BD,
lithium was an effective for both conditions in one RCT [15].
4.1.2. Depressive episodes
A 6-week prospective non-randomized cohort study in BD-I
depressed children and adolescents treated with lithium reported
response and remission rates of 48% and 30%, respectively, with a
large reduction in Children’s Depression Rating Scale-Revised
(CDRS-R) scores (standardized effect size Cohen’s d = 1.7) [28].
4.1.3. Prophylaxis
Three prospective non-randomized cohort studies reported
long-term positive response to lithium treatment [29,30], espe-
cially in those who responded to acute treatment with lithium [31].
In a 18-month prospective non-randomized cohort study, 35%
(N = 13/37) of patients who discontinued prophylactic lithium
therapy showed nearly three times higher relapse rates compared
Fig. 1. Flow diagram of selected articles.
*Search strategy limited to June 2018, English language, human subjects younger than 18 years old, and clinical trial.
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was associated with a greater risk of future relapse.
In contrast, an Indian prospective non-randomized cohort
study found that 64% (N = 16/25) of lithium-treated subjects
relapsed after 18  16.4 months (mean total follow-up duration
51.6  4.1 months). The majority of the relapses (72.4%) occurred
during prophylactic treatment. 28% (N = 7/25) and 36% (N = 9/25)
of relapsing patients had single and multiple relapses respectively,
with manic episodes being the most common polarity (N = 14/25,
58%) [32].
4.1.4. Offspring of manic-depressive patients
In a small RCT, 33% (N = 2/6) children, who met DSM-III criteria
for BD and were offspring of manic-depressive patients, responded
to lithium on both child and parent ratings and showed
augmentation of evoked potentials (EPs) similar to what is seen
in adults treated with lithium [33].
4.1.5. Lithium monotherapy vs. other psychotropic drugs
Five RCTs compared lithium monotherapy to other mood
stabilizers or antipsychotics [34–38]. In a 18-month RCT, dival-
proex was not found to be superior to lithium as maintenance
treatment in BD youths who had been stabilized on combined
lithium plus divalproex for four weeks [34].In a prospective non-randomized cohort study, lithium,
divalproex, and carbamazepine all showed a large and similar
effect size in treatment of acute manic or mixed episodes [36].
Compared to antipsychotics for initial treatment of acute manic
or mixed episode in children and adolescents, risperidone was
more efficacious than mood stabilizers but had more metabolic
side effects [35,37]. Also, risperidone was more effective than
lithium or divalproex for children with BD-I who were non-
responders or partial responders to another prior antimanic agent
[38].
4.2. Lithium in combination with adjunctive agents
As in adults, children and adolescents with BD frequently
required long-term combination therapy [39]. Therefore, adher-
ence became important [19]. A 6-month prospective non-
randomized cohort study demonstrated that lithium or divalproex
plus risperidone were equally efficacious and safe for manic and
mixed symptoms in pediatric mania [40]. In psychotic mania, one
study found that adjunctive antipsychotic medication needed to be
maintained longer than 4 weeks in the majority of adolescents [17].
As demonstrated by two prospective non-randomized cohort
studies, the combination of lithium and divalproex was effective in
treating acute manic and depressive symptoms in juvenile BD and
Table 1
Studies that met inclusion criteria for systematic review.
References Study design Country Study population N at entry/ Retained Diagnostic
assessment
Outcomes
[29] Prospective
non-
randomized
cohort
USA Pts (n = 59; mean
age = 11.4)
196, enrolled (59, bipolar; 29, depression;
11, EUCD; 19, ADD; 7, offspring of
Li + responder; 33, CD; 8, ADD/affective; 9,
affective/aggressive/explosive; 21,
Developmental disorder)
DSM Lithium effectiveness (clinical criteria)
[29] Prospective
non-
randomized
cohort
USA BD (n = 107; mean
age = 10.49)
107, completed K-SADS;
DSM-IV
Lithium effectiveness: CDRS-R40,
YMRS  12.5, CGAS  51 (for 4
consecutive weeks) [Remission]; Li + and
DVPX serum level
[41] Prospective
non-
randomized
cohort
USA BD (n = 90; mean
age = 10.9)
109, enrolled; 90, completed at least one
week
K-SADS, K-
SADS-E, K-
SADS-PL;
DSM-IV
Lithium effectiveness: #YMRS 50%,
CGI  2 [Response]; CDRS-R40,
YMRS  12.5, CGAS  51 (for 4
consecutive weeks) [Remission]
[34] RCT USA BD (n = 60; mean
age = 10.8)
60, treated (30, DVPX; 30 Li+) after
achieving remission on open-label DVPX-
Li + combination treatment
DSM-IV Lithium effectiveness: CDRS-R40,
YMRS  12.5, CGAS  51 [Remission]
[42] Prospective
non-
randomized
cohort
USA BD (n = 38 subjects;
mean age = 10.3)
40, enrolled; 38, completed at least one
week (19 Li + monotherapy, 19 DVPX
monotherapy during the randomized
maintenance monotherapy trial)
K-SADS;
DSM-IV
Lithium effectiveness: CDRS-R40,
YMRS  12.5, CGAS  51 [Remission]
[43] RCT USA BD-I (n = 39, manic or
mixed phase; mean
age = 11.8)
39, randomly assigned to Arm I (Li+,
600 mg/day) or Arm II (Li+, 900 mg/day)
K-SADS-PL,
YMRS  20,
WASI  70;
DSM-IV
Li + serum level
[14] RCT USA BD-I (n = 60, manic or
mixed phase; mean
age = 12.6)
61, enrolled; 60, completed at least 1
week of score (ARM I: 15, completed, Li+
300 mg/twice a day as starting dose; ARM
II, 13 completed, and ARM III, 12
completed, Li+ 300 mg/thrice a day as
starting dose)
DSM-IV Lithium effectiveness: #YMRS:  50%,
CGI  2 [Response]; #YMRS 25-50%,
CGI  3 [Partial response]; CGI  4 or
#YMRS<25% or inability to tolerate a dose
of 600 mg/day Li+ [Non responders]
[31] Prospective
non-
randomized
cohort
USA BD-I (n = 41, manic or
mixed phase; mean age
11.8)
105, screened for Phase I; 61, enrolled in
Phase I; 41, completed Phase I and were
enrolled in Phase II
YMRS; DSM-
IV
Lithium effectiveness: #YMRS:  50%,
CGI  2 [Response]; #YMRS 25-50%,
CGI  3 [Partial response]; YMRS  12,
CGI  2 [Remission]
[20] RCT USA BD-I (n = 58, manic or
mixed phase; mean age
11.3)
81, enrolled (53, Li+; 28, placebo),; 58,
completed
K-SADS-PL;
DSM-IV
Lithium effectiveness: #YMRS:  50%,
CGI-I2 [Response]; YMRS  12, CGI-S2
[Remission]
[15,16] RCT USA BD-SDD (n = 25
enrolled; mean
age = 16.3)
25, enrolled (13, Li+; 12, placebo),; 21,
completed
K-SADS, FH-
RDC; DSM-
III-R
Lithium effectiveness: CGAS  65
[Response]; Li + serum level; Urine drug
essays; Lithium side effects (ALSES)
[35] RCT USA BD (279, manic or mixed
phase; mean age = 10.1)
5671, screened; 290, antimanic
medication naive randomly assigned to Li
+ (90, completed), risperidone (89,
completed), DVPX (100 completed)
WASH-U-
KSADS,
CGAS; DSM-
IV
Lithium effectiveness: CGI-BP-IM2,
KMRS [Response]; Lithium side effects
[32] Prospective
non-
randomized
cohort
India BD (n = 25, mania; mean
age = 14.1)
26, enrolled; 25 completed a mean
duration of follow-up of 51.6  4.1 months
DICA-R;
DSM-IV
Lithium effectiveness: YMRS  12.5,
CGAS  51 [Remission]
[24] Retrospective
cohort
USA BD (n = 48, mania; mean
age = 15.7)
48, treated (25, mania; 23 psychotic
mania)
K-SADS-L,
YMRS > 16,
FH-RDC;
DSM-IV
Lithium effectiveness: #YMRS>33%,
CGI  2 [Response]
[17,18] Prospective
non-
randomized
cohort
USA BD (psychotic mania
n = 28; mean age = 15.9)
35, enrolled; 28, completed 4 weeks
(Li + and antipsychotic) (14,
Li + monotherapy)
YMRS; DSM-
IV
Lithium effectiveness: #YMRS>33%,
CGI  2 [Response]; YMRS  6
[Remission]
[17,18] Prospective
non-
randomized
cohort
USA BD (n = 10: psychotic
mania = 5, nonpsychotic
mania = 5; mean
age = 16.42)
10, treated (5, Li + and haloperidol; 5, Li+) YMRS; DSM-
IV
Lithium effectiveness: #YMRS>33%,
CGI  2 [Response]
[22] Prospective
non-
randomized
cohort
USA BD (n = 100, acute
mania; mean age = 15.2)
100, treated K-SADS-L;
DSM-IV
Lithium effectiveness: #YMRS>33%,
CGI  2 [Response]; YMRS  6
[Remission]
[25] RCT USA BD (n = 100, acute
mania; mean age = 15.2)
100, enrolled; 40, randomized (19, Li+; 21,
placebo)
K-SADS-L;
DSM-IV
Lithium effectiveness: #YMRS>33%,
CGI  2 [Response]; YMRS  6
[Remission]
[36] RCT USA BD (n = 42, acute phase,
manic or mixed; range
age = 6-18)
42, treated (14, lithium; 15, DVPX; 13,
CBZ)
YMRS; DSM-
IV
Lithium effectiveness: YMRS and CGI
#50% [Response]
[39] Prospective
non-
randomized
cohort
USA BD (n = 35: mania = 17,
hypomania = 18; mean
age = 11)
42, enrolled; 35, elected to continue (18
acute-phase responders, 17 acute phase
non-responders)
K-SADS;
DSM-IV
Lithium effectiveness: CGI  2,
#YMRS50% [Response]
[21] RCT USA
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Table 1 (Continued)
References Study design Country Study population N at entry/ Retained Diagnostic
assessment
Outcomes
BD (n = 61, manic or
mixed phase; mean
age = 13)
61, enrolled; 41, completed phase I; 21,
completed phase II
YMRS; DSM-
IV
Lithium effectiveness: YMRS and CGI
#50% [Response]
[33] Prospective
non-
randomized
cohort
USA Offsprings of manic-
depressive pts whose
parents were
Li + responders (n = 6;
mean age = 10.8)
6, treated SADS, CPRS,
CARS; DSM-
III
Lithium effectiveness (clinical criteria);
Average evoked potentials
[44] Cross-
sectional
USA BD-I (n = 9, children,
mean age 13.4; n = 18,
adults, mean age = 37.3)
9, examined with In Vivo Magnetic
Resonance Spectroscopy
DSM-IV Serum and brain Li + concentrations
[28] Prospective
non-
randomized
cohort
USA BD-I (n = 20, depression;
mean age = 15.6)
53, screened; 27, enrolled; 20, completed
all 6 weeks
WASH-U-
KSADS,
CDRS-R40,
Y-MRS20;
DSM-IV
Lithium effectiveness: #CDRS-R50%
[Response]; CDRS-R28 and CGI-BD2
[Remission]
[40] Prospective
non-
randomized
cohort
USA BD (n = 37; mean
age = 12.1)
40, enrolled; 37, completed at least one
month (17, Li + and risperidone; 20, DVPX
and risperidone)
YMRS,
WASH-U-
KSADS;
DSM-IV
Lithium effectiveness: #YMRS50%
[Response]; #YMRS50%, CGI  2,
CGAS  51 [Remission]
[37] RCT USA BD-I (n = 210, manic or
mixed phase; range
age = 6-15)
279, enrolled; 210, completed (61, Li+; 74,
DVPX; 75, risperidone)
WASH-U-
KSADS;
DSM-IV
Lithium effectiveness: CGI-BP-I-D2,
CDRS-R2 [Response]
[23] Prospective
non-
randomized
cohort
USA BD (n = 50; range
age = 13-17)
50, treated (15, prepubertal onset; 35,
adolescent onset)
DSM-III Lithium effectiveness: CGI  2 [Response]
[30] Prospective
non-
randomized
cohort
USA BD-I (n = 24; mean
age = 15.1)
37, enrolled; 24, completed RSMS;BHS;
DSM-III
Lithium effectiveness: HAM-D7
[Stable]; #BHS50%, #MSRS 50%, CGI  2
for 4 weeks [Response]
[27] Prospective
non-
randomized
cohort
USA BD-I (n = 60, mania;
mean age = 15.2)
60, treated (30 with, and 30 without a
prior history of early childhood ADHD)
DSM-III-R or
DSM-IV
Lithium effectiveness: CGI  2 or
BMRS  50 [Response]
[26] RCT USA BD-I (n = 279; mean
age = 10.1)
279, enrolled (90, Li+; DVPX, 100; 89,
risperidone)
WASH-U-
KSADS;
DSM-IV
DSM-IV
Lithium effectiveness: CGI-BP-IM2
[Response]
[38] RCT USA BD-I (n = 99, manic or
mixed phase; range
age = 6-15)
154, enrolled; 99, completed (42, Li+; 27,
DVPX; 30, risperidone)
WASH-U-
KSADS;
DSM-IV
Lithium effectiveness: CGI-BP-IM2,
KMRS  11 [Response]
BD: Bipolar disorder; PMDD: Prepubertal major depressive disorder; MDD: Major Depressive Disorder; DBD: Disruptive behavior disorder; SDD: Substance dependency
disorders; EUCD: Emotionally Unstable Character Disorder; ADD: Attention Defict Disorder; CD: Conduct disorder; Li+: lithium carbonate; DVPX: divalproex sodium; CBZ:
carbamazepine; MPH: Methylphenidate; SGA: Second generation antipsychotic; DSM: Diagnostic and Statistical Manual of Mental Disorders; TEAM: Treatment of Early Age
Mania; K-SADS: Kiddie Schedule for Affective Disorders and Schizophrenia; K-SADS-P: Kiddie Schedule for Affective Disorders and Schizophrenia for Psychopatology; K-
SADS-E: Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version; K-SADS-PL: Schedule for Affective Disorders and
Schizophrenia for School Age Children-Present and Lifetime Version; WASH-U-KSADS: Washington University in St. Louis Kiddie Schedule for Affective Disorders and
Schizophrenia; CGI: Clinical Global Impression Scale; CGI-I: Clinical Global Impression-Improvement Scale; CGI-S: Clinical Global Impression-Severity Scale; CGI-BD: Clinical
Global Impressions Improvement Scale for Bipolar Disorder; CGI-BP-IM: Clinical Global Impressions for Bipolar Disorder Improvement-Mania; YMRS: Young Mania Rating
Scale; CDRS-R: Children’s Depression Rating Scale Revised; CGAS: Children’s Global Assessment Scale; BPRS: Brief Psychiatric Rating Scale; HAM-D: Hamilton Depression
Rating Scale; ABC-C: Aberrant Behavior Checklist – Community Edition; VAS: Visual analog scale for behavior; VABS: Vineland Adaptive Behavior Scale; FH-RDC: Family
History Research Diagnostic Criteria; SMD: Severe Mood Dysregulation; PANSS: Positive and Negative Syndrome Scale; CPT: Continuous Performance Test; K-PAL:
Kinsbourne’s computerized version of the Paired Associated Learning paradigm; ACTeRS: Attention Deficit Disorder-Hyperactivity Comprehensive Teacher Rating Scale; IGRS:
Inpatient Global Rating Scale; OAS: Overt Aggression Scale; MAOS: Modified Overt Aggression Scale; CBRS: Conners Bahavior Rating Scale; CTRS: Conners Teacher Rating
Scale; RT: Reaction Time Task; CSRS: Conner's Symptom Rating Scale; MFF: Matching Familiar Figures: STRM: Short-term Recognition Memory; CAT: Concept Attainment
Task; PANESS: Physical and Neurological Examination for Soft Signs; MPA: Minor Physical Anomalies; WISC-R: Wechsler Intelligence Scale for Children Revised; CPRS:
Children’s Psychiatric Rating Scale; CTQ: Conners Teacher Questionnaire; PTQ: Parent Teacher Questionnaire; TORSA: Timed Objective Rating Scale for Aggression; DOTES:
Dosage Record and Treatment Emergent Symptoms; GCCR: Global Clinical Consensus Rating; TESS: Treatment Emergent Symptoms Scale; GCJCS: Global Clinical Judgements
Consesus Scale; POMS: Profile of Mood States; TSCRS: Teacher’s Self Control Rating Scale; Mini-Kid: Mini International Neuropsychiatric Interview for Children and
Adolescents; CGI-BP-IM: Clinical Global Impressions for Bipolar Illness-Improvement Mania Scale; DICA-R: Diagnostic Interview for Children and Adolescents Revised; GAS:
Global Assessment Scale (for subjects who were over 16 years of age at follow-up); MSEFCA: Modified Side Effect Form for Children and Adolescent; ALSES: Acute Lithium Side
Effects Scale; FH-RDC: Family History Research Diagnostic Criteria; CARS: Children’s Affective Rating Scale; AIMS: Modified Abnormal Involuntary Movement Scale; PSSAC-R:
Psychosocial Schedule for School-Age Children Revised; WASI: Wechsler Abbreviated Scales of Intelligence; CDRS-R: Children’s Depression Rating Scale-Revised; RCT:
Randomized controlled trial.
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Table 2
Efficacy results and side effects of selected studies.
References Study design Sample
size
Target serum level/ Dose/ Mean
Serum Level Achieved/ Mean
medication duration
Concurrent
medications
Efficacy results Side effects*
Lithium monotherapy
Manic or mixed episodes
[14] RCT 60 Mean serum level achieved, 1.05
mEq/L (at the end of the study); ARM
I, 1.15 mEq/L; ARM II, 0.96 mEq/L;
ARM III, 1.05 mEq/L
None Of the 61 youths [32 males (52.5%)]
who received open-label lithium, 60
youths completed at least 1 week of
treatment and returned for a
postbaseline assessment; most pts
had an improvement in YMRS of
50%, and more than half of the pts
(58%) achieved response; all 3
treatment arms had similar
effectiveness, tolerability, side effect
profile.
Vomiting, headhache,
abdominal pain, tremor, "TSH
[20] RCT 58 Mean dose, 1292  420 mg/day (age
7-11), 1716  606 mg/day (12-17);
Mean serum level achieved,
0.98  0.47 mEq/L
None YMRS score larger in Li+-treated
participants (5.51[95% CI:0.51-
10.50]) after adjustment for baseline
YMRS score, age group, weight
group, gender, and study site. CGI–I
scores favored Li+ (47%) compared
with placebo (21%) at week 8/ET.
Thyrotropin concentration
increased with Li+
(3.0  3.1mIU/L) compared
with placebo (–0.1  0.9mIU/
L).
[25] RCT 100 Target serum level, 0.6–1.2 mEq/L;
Serum level achieved, 0.99  0.21 (at
randomization)
AP, BDZ Response rates: 20% in pts with
psychotic or aggressive symptoms,
60.3% in pts without. No significant
differences in exacerbation rate (Li+,
52.6% vs. placebo, 61.9%)
NS
[21] RCT 61 Mean serum level achieved, 0.8-1.2
mEq/L (Maximum trough
concentration, 1.4 mEq/L)
None A daily lithium carbonate dose of
25 mg/kg total body weight
(rounded to 300-mg capsules) in
two doses/day was predicted to
achieve a 50 % Young Mania Rating
Scale reduction in 74 % of patients,
with approximately 8 % of patients
expected to have trough
concentrations above the nominal
safety threshold of 1.4 mEq/L.
NS
[26] RCT 279 Mean serum level achieved, 1.09
mEq/L; DVPX: Mean serum level
achieved: 113.6 ug/L; Risperidone:
Mean dose: 2.57 mg/day
NS RR for risperidone vs. Li + ranged
from 1.2 (95%CI 0.8, 1.7) to 8.3 (1.1,
60.8), and for risperidone vs. DVPX
from 1.3 (0.8, 2.2) to 10.5 (1.4, 77.7);
RR for risperidone vs. Li + was 2.1 for
patients with ADHD, but 1.0 for
those without ADHD, and 2.3 (1.6,
3.3) for non-obese patients, but 1.1
(0.6, 2.0) for obese ones
NS
[17,18] Prospective
non-
randomized
cohort
10 Mean dose, 1560 mg/day; Man
serum level achieved, 0.93 mEq/L
Haloperidol Under haloperidol treatment, all pts
had full resolution of psychotic
features and significant declines
across all measures at the end of
week-1. However, within 1 week of
haloperidol discontinuation
(mean = 4.7days, range 17 days), all
pts had clinically significant return
of their psychosis and/or agitation
despite ongoing treatment with Li+
(mean dose = 1560 mg/day; mean
Li + level = 0.93mEq/L). In contrast to
the group with psychosis where
none of pts was rated as a responder,
60% of non psychotic pts were
responders to 4 weeks of
Li + monotherapy.
NS
[22] Prospective
non-
randomized
cohort
100 Target serum level, 0.6–1.2 mEq/L;
Dose, 1355  389 mg/day; Serum
level achieved, 0.93  0.21 mEq/L
AP, BDZ Response rates: 63%; Effect size:
1.48, YMRS; 1.21, CGAS; 1.40, GCI.;
26% pts achieved remisison of manic
symptoms; 83% pts showed
reduction in suicidality.
Polydipsia, "weight or appetite
(> 10% Pt. at week-4)
[23] Prospective
non-
randomized
cohort
50 Target, 0.9–1.5 mEq/L AP Response rate (at 6 weeks): 68% (80%
adolescent onset; 40% prepubertal
onset)
Rash, tremor
[27] Prospective
non-
randomized
cohort
60 Target serum level, 0.9–1.5 mEq/L;
Mean serum level achieved, 1.12
mEq/L
AP BRMS scores decreased by a mean of
24.3 in the subgroup without prior
ADHD compared to 16.7 in pts with
ADHD. The average percent drop in
Rash, tremor
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BRMS scores over the study period in
these two subgroups was 80.6% and
57.7%, respectively. Median time to
onset of sustained improvement was
lengthened significantly in patients
with early ADHD (23 days)
compared to those without it (17
days; log rank χ2 = 57.2).
[24] Retrospective
cohort
48 NS Haloperidol Response rate: 53.5% (23/43) (70.8%,
non-psychotic and 31.6%, psychotic).
Subjects without a childhood
psychiatric diagnosis declined from
a mean of 30.25 (SD = 9.31) at
baseline to 9.96 (SD = 8.00) at the
end of treatment; subjects with a
childhood diagnosis of ADHD had a
mean initial score of 27.72
(SD = 6.98) at baseline and a mean
score of 14.78 (SD = 8.98) at the end
of the protocol; decline in mean
scores across both groups was
statistically significant (F=41.40,
df=1.19).
NS
Depressive episodes
[28] Prospective
non-
randomized
cohort
20 Dose adjusted to obtain serum level
of 1-1.2 mEq/L
None Mean CDRS-R scores decreased from
baseline to endpoint (mean [SD]
change =-25.5, SD = 20.4), effect
size = 1.7. Response and remission
rates, 48% and 30%.
Headhache, nausea, vomiting,
stomachache, abdominal
cramps
Prophylaxis
[15,16] RCT 25 Target serum level, 0.9–1.3 mEq/L;
Dose, 1769  401 mg/d; Serum level
achieved, 0.98  0.33 mEq/L
NS Intent-to-treat response: 46.2%,
Li + vs 8.3%, placebo; completer
group response: 60%, Li + vs 9.1%,
placebo; no differences between
groups for mood or SDD symptoms.
Polydypsia, polyuria
[29] Prospective
non-
randomized
cohort
59 Dose, 400-1200 mg/day; Serum
levels, 0.5-1.2 mEq/L
NS Diagnosis successfully treated:
manic-depression (66%), depression
(17%) ADD 0%, EUCD (82%), CD (15%),
ADD affective (38%), affective/
aggressive/explosive (56%),
developmental disorder (29%),
offspring of Li + responder (71%).
Thyroid enlargement without
hypothyroidism (1 Pt.)
[31] Prospective
non-
randomized
cohort
41 Dose, 27.8 mg/kg/day (at the and of
Phase-2); Mean serum level
achieved, 1.0 mEq/L
DVPX, MPH,
risperidone
41 pts received continued open-label
long-term treatment with lithium
for a mean of 14.9 (3.0) weeks during
Phase II; the mean weight-adjusted
total daily dose at end of Phase II was
27.8 (6.7) mg/kg/day, with an
average lithium concentration of 1.0
(0.3) mEq/L; 60.9% Pt. (26/41) were
prescribed adjunctive psychotropic
medications for residual symptoms;
the most frequent indications for
adjunctive medications were
refractory mania (n = 13; 31.7%) and
ADHD (n = 15; 36.6%); at the end of
this phase 28 (68.3%) pts met a priori
criteria for response, with 22 (53.7%)
considered to be in remission.
Vomiting, headhache,
abdominal pain, tremor
[32] Prospective
non-
randomized
cohort
25 Mean dose, 1074 mg; Serum level
achieved, 0.8-1.2 mEq/L
Clorpromazine,
haloperidol,
risperidone,
CBZ, DVPX,
imipramine
64% (16/25) of pts relapsed after a
mean period of 18  16.4 months;
72.4% of the relapses were while the
subjects were on treatment and the
majority of them (87%, 20/23)
occurred while the pts were on
lithium (alone or in combination).
NS
[30] Prospective
non-
randomized
cohort
24 Target serum level, 0.6–1.2 mEq/L;
Serum level achieved, 0.7–1.4 mEq/L
(at stabilization),0.79 mEq/L (at end
of 18 month)
AP, CBZ 56.8% (21/37) pts relapsed; relapse
rate higher in non completers
(92.3%) than in completers (37.5%).
Completers who had had previous
episodes showed a decline in the
mean  SD number of episodes
during the follow-up (1.70, SD = 0.78
vs. 0.8, SD = 1.00).
NS
Offspring of manic-depressive patients
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[33] Prospective
non-
randomized
cohort
6 Serum level achieved, 0.8-1.2 mEq/L None Response rates: 33% (2/6); these pts
were strong augmenters on the EP.
NS
Lithium monotherapy vs. other psychotropic drugs
[34] RCT 60 Target serum level, 0.6–1.2 mEq/L;
Dose, 30 mg/kg/d; Serum level
achieved, 94  0.26 mEq/L; DVPX:
Target serum level, 50–100 mg/mL;
Dose, 20 mg/kg/d; Serum level
achieved, 81.1  20.5 mg/mL
Stimulants 63.5% of youths exited the study for
mood-related reasons (60%, Li+;
66.7%, DVPX); time to mood relapse
did not differ between the Li and
DVPX treatment groups (log-rank [1
df] = 0.35); the two treatment
groups did not differ in time until
study discontinuation for any reason
(log-rank [1 df] = 0.13); youths with a
younger age of onset were more
likely to relapse; youths with higher
YMRS scores at baseline were more
likely to discontinue study early.
Emesis, enuresis, headache,
stomach pain
[35] RCT 279 Mean serum level achieved,
1.09 mmol/L; Dose 872 mg/day;
DVPX: Mean serum level achieved,
113.6 ug/mL; Rsperidone: Mean
dose, 2.57 mg
MPH Higher response rates occurred with
risperidone vs Li+ (68.5% vs 35.6%;
χ2 = 16.9) and vs DVPX (68.5% vs
24.0%; χ2 = 28.3). Response to Li + vs
DVPX did not differ; the
discontinuation rate was higher for
Li + than for risperidone (χ2 = 6.4).
Abdominal pain, weight gain/
loss, headache, dry mounth,
nasal congestion, frequent
urination, excessive thirst,
"TSH
[36] RCT 42 Target serum level, 0.8–1.2 mEq/L;
Dose, 30 mg/kg/day; Serum level
achieved, 0.88  0.35 mEq/L; DPVX:
Target serum level, 85–10 mg/mL;
Dose, 20 mg/kg/day; Serum level
achieved, 82.8  22.92 mg/mL; CBZ:
Target serum level, 7–10 mg/L; Dose,
15 mg/kg/day; Serum level achieved,
7.11  1.79 mg/L
Chlorpromazine Effect size: 1.63, DVPX; 1.06, Li+;
1.00, CBZ. Response rates: 53%,
DVPX; 38%, Li+; 38%, CBZ (χ2 = 0.85)
Nausea, "appetite
[37] RCT 210 Mean serum level achieved, 1.09
mEq/L; DVPX: Mean serum level
achieved: 113.6 ug/L; Risperidone:
Mean dose: 2.57 mg/day.
DVPX,
risperidone
CGI-BP-I-D ratings better in the
risperidone group (60.7%) as
compared to the Li+ (42.2%) or DPVX
(35.0%) groups from baseline to the
end of the study. CDRS scores in all
treatment groups improved equally
by study end. In week 1, scores were
lower with risperidone compared to
DPVX (mean = 4.72, 95% CI = 2.67,
6.78), and compared to Li+
(mean = 3.63, 95% CI = 1.51, 5.74),
although group differences were not
present by the end of the study. No
overall effect of treatment on
suicidality ratings.
NS
[38] RCT 99 Endpoint blood levels or dose in the
complete sample of treatment-naive
participants: Li+ 0.75  0.4 mEq/mL;
DPVX 85.5  36.3 mg/mL; and
risperidone 2.3  1.2 mg daily.
Among treatment-naive responders:
Li+ 0.89  0.3 mEq/L; DPVX,
88.7  45.2 mg/mL; risperidone was
2.3  1.2 mg daily. Among partial
responders who received add-on
treatment: Li+ 0.70  0.5 mEq/L;
DPVX, 61  37.5 mg/mL; risperidone
was 2.1  1.7 mg daily. Among non-
responders: Li+, 1.09  0.3 mEq/L;
DPVX, 114  23 mg/mL; risperidone,
2.6  1.2 mg.
DVPX,
risperidone
Response rate for children switched
to risperidone (47.6%) was higher
than for those switched to either Li+
(12.8%; NNT = 3; 95% CI = 1.71–9.09)
or DVPX (17.2%; NNT = 3; 95%
CI = 1.79–20.10). Response rate for
partial responders who added
risperidone (53.3%) was higher than
for those who added divalproex (0%;
NNT = 2; 95% CI = 1.27–3.56) and
trended higher for lithium (26.7%;
NNT = 4).
Weight gain (kg) was observed
for all add-on medications:
Li + add-on = 1.66  1.97;
risperidone add-
on = 2.8  1.34; DPVX add-
on = 1.42  1.96.
Lithium in combination with adjunctive agents
[17,18] Prospective non-
randomized
cohort
28 Target serum level, 0.6–1.2 mEq/L;
Mean serum level achieved, 0.88
mEq/L; Haloperidol: Dose, 5–10 mg/
day; Risperidon: Dose, 6 mg/day
BDZ Response rate to combination
treatment: 64.3%; 57% (8/14) stable
on monotherapy for 4 weeks.
Succesfull discontinuation of
antipsychotic is associated with first
episode, shorter duration of
psychosis, presence of thought
disorder at baseline.
71% minimal, 22.9% moderate
functional impairment (mainly
GI symptoms)
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[39] Prospective non-
randomized
cohort
35 Target serum level, 0.8–1.2 mEq/L;
Dose, 30 mg/kg/d; Serum level
achieved, 0.88  0.35 mEq/L; DPVX:
Target serum level, 85–110 mg/ml;
Dose, 20 mg/kg/d; Serum level
achieved, 82.8  22.92 mg/ml
CBZ: target, 7–10 mg/L; dose, 15 mg/
kg/d; achieved, 7.11  1.79 mg/L
MS, AD, AP,
Stimulants
58% (20/35) of pts required
treatment with one or two mood
stabilizers and either a stimulant, an
atypical antipsychotic agent, or an
antidepressant agent. Response rate
to combination therapy: 80% of
subjects treated responding to
combination therapy with two mood
stabilizers after not responding to
monotherapy with a mood stabilizer.
Nausea, "appetite
[40] Prospective non-
randomized
cohort
37 Target serum level, 0.6–1.0 mEq/L;
Dose, 10–30 mg/kg/day
(750  400 mg/day); Mean serum
level achieved, 0.9 mEq/L;
Risperidon: Target serum level,
0.25–0.50 mg/day to max 3 mg/day;
DPVX: Target serum level, 50–
120 mg/mL; Dose, 15–20 mg/kg/day
(925  325 mg/day); Mean serum
level achieved, 106 mg/mL
Stimulants,
Clonidine,
Benzotropines,
Trazodone
Effect sizes (Cohen’s d) based on
change of YMRS scores from baseline
were 4.36 for DVPX-risperidone and
2.82 for Li+-risperidone. Response
rates: 80% for DVPX + Risp and 82.4%
for Li+-risperidone.
Weight gain, sedation, nausea
[19] Prospective non-
randomized
cohort
107 Mean serum levels, 0.6-1.2 mmol/L None Maternal (r = -0.31) and paternal (r =
-0.44) hospitalization for a
psychiatric disorder and less
adaptive family functioning (r =
-0.26) related to treatment
nonadherence for DVPX. Better
treatment adherence to DVPX
(r = 0.21) and Li+ (r = 0.23) was
associated with a greater number of
side effects, whereas male sex was
associated with worse adherence to
both DVPX (r = -0.24) and Li+ (r =
-0.22) pharmacotherapy. Clinical
response to treatment correlated
with adherence to DVPX treatment
(r = 0.33).
NS
[41] Prospective non-
randomized
cohort
90 Target serum level, 0.6–1.2 mEq/L;
Dose, 30 mg/kg/day
(923.3  380.2 mg/day); Serum level
achieved, 0.9  0.3 mEq/L; DVPX:
Target serum level, 50–100 mg/ml;
Dose, 20 mg/kg/day
(862.5  397.5 mg/day); Serum level
achieved, 79.8  25.9 mg/ml
Stimulants, AP,
AD, α2agonist
Response rates (8 weeks): 70.6%
(YMRS), 59.3% [CGI]. Remission:
46.7%.
Polydipsia, polyuria, emesis,
headache, tremor, "appetite
[42] Prospective non-
randomized
cohort
38 Mean serum levels, 0.83 mmol/L (at
the end of the study); Mean dose,
872 mg/day; DVPX: Mean serum
level achieved, 75.5 ug/mL (at the
end of the study); Mean dose
833 mg/day
MPH,
olanzapine,
risperidone,
clonidine
89.5% (34/38) pts responded to
treatment with Li+/DVPX mood
stabilizer therapy alone; four pts
required adjunctive antipsychotic
treatment to address residual
symptomatology; reinitiation of Li
+/DVPX combination therapy was
well tolerated with no pts
discontinuing because of a
medication-related adverse event.
Emesis, enuresis, headache,
"appetite
BD: bipolar disorder; EUCD: emotionally unstable character disorder; ADD: attention defict disorder; CD: conduct disorder; ADHD: attention deficit/hyperactivity disorder;
SMD: Severe mood dysregulation; SDD: substance dependency disorders; Li+: lithium carbonate; DVPX: divalproex sodium; CBZ: carbamazepine; BDZ: benzodiazepines; AP:
Antipsychotics; AD: Antidepressants; MS: Mood stabilizers; MPH: Methylphenidate; NAA: N-acetyl-aspartate; YMRS: Young Mania Rating Scale; CPRS: Children’s Psychiatric
Rating Scale; GCJCS: Global Clinical Judgments Consensus Scale; BRMS: Bech–Rafaelsen Mania Scale; ABC-C: Aberrant Behavior Checklist – Community Edition; CGI: Clinical
Global Impression Scale; OAS: Overt Aggression Scale; VABS: Vineland Adaptive Behavior Scale; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status;
CPT: Continuus Performance Test; K-PAL: Kinsbourne’s computerized version of the Paired Associated Learning paradigm; PSSAC-R: Psychosocial Schedule for School-Age
Children Revised; CGAS: Children’s Global Assessment Scale; CDRS-R: Children’s Depression Rating Scale Revised; MTD: maximum tolerated dosage; GI: Gastrointestinal;
TSH: thyroid stimulating hormone; SD: standard deviation; RR: response ratio; pts: patients; RT: reaction time; NS: Not specified; Vs.: Versus; EP: evoked potentials; NNT:
Number needed to treat; *Related to the use of lithium; RCT: Randomized controlled trial; Differences statistically significant (p < 0.05).
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lithium plus divalproex sodium but later relapsed with mono-
therapy of one agent [41,42].
5. Starting dose and dosing strategy
In patients with BD-I, two phases in the distribution of lithium
was observed, with an initial half-life of 2.4 h and a later half-life of
27 h [43]. Multiple dose simulations suggested that a starting dose
of 300 mg once daily for those weighing less than 30 kg, and
300 mg twice or three times daily for youths weighing 30 kg or
more, appear to be appropriate based on safety margins for trough
concentrations. Later trials from the same research group observed
a good tolerability of starting dose of 900 mg/day for most subjects
[14,20].
6. Brain-to-serum lithium association
A cross-sectional study conducted on BD-I patients showed a
positive correlation between serum and brain lithium concen-
trations, with younger subjects having lower brain-to-serum
concentration ratios than adults (0.58, SD = 0.24 vs. 0.92, SD = 0.36)
[44]. According to these results, children and adolescents may
need higher maintenance serum lithium concentrations than
adults to reach similar brain lithium concentrations.
7. Safety and tolerability
Lithium’s recommended target dose in children and adoles-
cents is 30 mg/kg/day, with 0.6–1.2 mEq/L serum levels [45] even
though other authors [14,20] suggest more aggressive dosing,
particularly for acute manic or mixed episodes. For instance, the
FDA recommends dosing lithium until therapeutic response or a
maximal blood level of 1.4 mEq/L is achieved or a dose-limiting
side effect is present. Studies in this review tended to be within
those guidelines, with 10–30 mg/kg/day dosages range, 0.6–1.5
mEq/L serum levels (Table 1). Most of the selected studies reported
side effects in the mild to moderate range, with low dropout rates.
No serious adverse events were reported either with lithium
monotherapy or in combination with other psychotropic drugs
(Table 1). Obviously, close serum level monitoring is required to
ensure that lithium is safe and well-tolerated.
The most common side effects of lithium in children and
adolescents were gastrointestinal symptoms (including nausea,
vomiting, diarrhea, abdominal cramps, stomach pain), tremor,
polyuria, polydipsia, and enuresis (Table 1). Only a minority of
patients presented hypothyroidism with increased thyroid stimu-
lating hormone [20] and/or thyroid enlargement [14,29]. Most of
the studies report an increase in appetite and weight gain, which is
a problem with several other BD agents [46]. However, this
difference was not statistically different from placebo [20]. No
cases of acute kidney injury or chronic kidney disease were
reported.
8. Discussion
This study is the first systematic review to look specifically at
the use of lithium in children and adolescents with BD. Thirty
studies were included. Almost sixty percent of subjects were
studied in RCTs (n = 12 studies) that evaluated lithium efficacy in
acute manic-mixed episodes, and as a prophylactic agent. Lithium
was effective in monotherapy and in combination with anti-
psychotics for treating acute manic and mixed episodes. Lithium
showed a greater response in manic episodes without psychotic
symptoms, and in the absence of ADHD comorbidity. Adolescents
had a better response than prepubescent children, andprophylactic efficacy was superior to divalproex and proportional
to acute response [31]. Lithium also was effective in treating BD
with secondary substance use disorder.
It is unclear whether lithium is effective in treating bipolar
depression in children and adolescents. The only study that
evaluated lithium efficacy on bipolar depression in youth [28]
found relatively low response rates that are in line with previous
results in depressed children with a family history of BD [16] and in
adults [47].
Lithium appears generally safe for use by children and
adolescents with only mild-moderate side effects. Its long-term
risks also do not appear to be notable, at least as identified so far,
and seem consistent with the adult literature. No cases of renal
failure were observed in the sample of over 2000 subjects included
in this systematic review, but this is probably explained by the
short follow-up. In fact, accordingly to the literature, long-term
patients (generally after 10–20 years of treatment) have an
increased risk to develop impaired renal function due to a slowly
progressive chronic interstial nephritis. Hypothyroidism was
observed, though only in a minority of patients.
All the RCTs that found a lower efficacy of lithium compared to
risperidone [26,35,37,38] were from the Treatment of Early Age
Mania Study (TEAM).
8.1. Epidemiological and clinical background of BD in children and
adolescents
In the past, with the exception of a few experts, like Kraepelin
and Ziehen, bipolar illness in children essentially was not
considered a diagnostic possibility until recently. Estimated
prevalence in adolescence varies from 1.8% [48] to 2.5% [49],
being slightly higher in the US than in Europe. In 2011, the World
Health Organization listed bipolar spectrum disorder as the fourth
leading cause of disability among adolescent ages 15–19 years
worldwide [50]. Annual rates of BD diagnosis [51] and related
hospitalization [52] in youth are increasing. Compared to adult-
onset BD, children and adolescents experience more symptoms,
comorbidities and mood switches and have a poorer prognosis
[53,54]. Because BD is a recurrent condition with more than 70% of
subjects relapsing by early adulthood [55], it is important to treat
prophylactically even in childhood, when it is often misdiagnosed
[56] or left untreated [57].
8.2. Comparison with FDA recommendations and main guidelines
In the paediatric population, lithium is the only mood stabilizer
with a US Food and Drug Administration (FDA) indication for acute
mania and maintenance treatment of BD and it is licensed for
treatment of acute mania in the UK [58,59]. Clinicians still display
qualms about lithium [60,61], with BD children and adolescents
receiving complex treatment regimens, often involving multiple
psychotropic drugs; only 2% receive lithium monotherapy [62].
Effective treatments in BD youths are still withheld or
underused. More than one third of children with BD receive two
or more medications belonging to different classes (i.e. mood
stabilizers, antipsychotics, antidepressants or stimulants) feeding
the problem of off-label prescriptions [63].
The US FDA also has approved risperidone, aripiprazole,
quetiapine, olanzapine, olanzapine in association with fluoxetine,
lurasidone and asenapine for the treatment of BD in youth; the
higher efficacy of risperidone above lithium in the two trials
available might have been driven by the high comorbidity rates in
the study populations, or it may reflect more rapid acute onset of
effect [58]. Aripiprazole, the only antipsychotic licensed in the UK
for paediatric BD, is comparable in efficacy to traditional mood
stabilizers [64].
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Many second-generation antipsychotics are associated with a
greater burden of metabolic side effects that, along with the recent
warning about the use of antipsychotic in children and adoles-
cents, could argue in favour of mood stabilizers [65–67]. In fact,
lithium side effects (e.g. nausea, hand tremor, thirst and polyuria,
diarrhoea) are dose-dependent and, although relatively frequent
[68], are only mild-moderate in effect size. Cognitive effects also
need to be considered, with a recent study finding impairment in
executive control in adolescents treated with lithium [69]; another
prior study did not find such cognitive impairment though [70].
Lithium treatment in adolescents is associated with an increase in
blood TSH levels in up to 25% of the subjects [71]. In this systematic
review, only one subject had clinically significant thyroid
impairment.
It also is important to note that no cases of acute kidney injury
or chronic kidney disease were observed. Still, serial monitoring of
renal and thyroid functioning is recommended [71,72].
In sum, special concern about the use of lithium in children and
adolescents, at least on safety grounds, seems unwarranted based
on this systematic review.
9. Limitations
The main limitation of this systematic review is linked to the
characteristics of the selected studies, such as brevity of follow-up
periods, small sample sizes, and analysis strategies (Table 1). Small
sample sizes and enrolment of subjects mainly from US sites
(almost 94%) may limit generalizability. Potential confounding
factors in these studies include demographic and historical illness
variables in non-randomized trials, which often were not
appropriately analysed through multivariate modelling. The
inclusion of only BD studies might limit the results regarding
lithium tolerability in children and adolescents [11,12].
The main strength of this systematic review is linked to the
inclusion of 12 RCTs (Table 1), which would limit the effect of
confounding variables Further, this review was systematic,
including the entire scientific evidence published so far. Also,
diagnoses were consistently based on DSM criteria and were
established by trained investigators using validated assessment
scales mainly with interrater reliability. This is particularly
relevant because one of the main features of BD is mood instability
and it is easy to attribute mood swings to the behavioural
vicissitudes of adolescence or to psychosocial changes [73].
Moreover the comorbidity rate in BD in youth is more than 80%
[74–76], with up to 50% for anxiety disorders [77]. Thus, in mild
cases, adjustment disorders are frequently diagnosed [78]. The
debate about the possibility of broadening the diagnosis of BD in
youth to a larger spectrum remains open [79]. Future studies
should better define this diagnostic spectrum in order to allow
better study of drug efficacy.
10. Clinical implications
The results of this systematic review, showing efficacy and
safety of lithium in children with BD, are in line with clinical
recommendations in literature. According to guidelines for
children and adolescents with BD [80,75,76], lithium is considered
a first line treatment and can be prescribed in monotherapy for up
to 8 weeks, if there are no psychotic features. If there are psychotic
features, treatment combining a mood stabilizer and an antipsy-
chotic is recommended.
Lithium should be considered if there is a comorbid substance
use disorder, which has high frequency in this population and
portends poor prognosis [10].Overall, these results in children somehow overlap with those
in adults which find efficacy with lithium [81,82], benefit with
lithium in preventing suicide [83], and general tolerability of
lithium [5]. Similarly, when accounting for body size, the
pharmacokinetic parameters in paediatric patients were within
the range of estimates from adults [21]. As in adults [84], lithium
discontinuation in BD after successful maintenance monotherapy
is not advisable.
Moreover, children who are treated with lithium are less likely
to show mood instability, impulsivity and self-injurious behaviour,
identity confusion, and interpersonal problems [60], all of which
are poor prognostic factors [85].
To date, the field of child and adolescent psychiatry lacks
validated prophylactic therapy for depressive and bipolar illness,
and little is known about the benefit-cost ratio of long-term
treatment with lithium. Progress in this area would serve to shed
light on the best balance between efficacy and side effects in
clinical settings. Future research efforts may lead to more
grounded guidelines, which are greatly needed in child and
adolescent psychiatry.
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